Drug Information Association Logo

DIA to Host Webinar: Measurement In Clinical Trials: An Examination of the FDA Position on the Review of Clinical Outcome Assessments

WASHINGTON — Sep 4, 2013

DIA today announced the third in its four-part Solution Provider educational webinar series held in cooperation with ICON plc.  On September 12, 2013, DIA will host: Measurement in Clinical Trials: An Examination of the FDA Position on the Review of Clinical Outcome Assessments. ICON is the first to collaborate with DIA’s newly-created Solution Provider Webinar Program. DIA’s educational partnership with ICON will bring together leading scientists and thought leaders from the biopharma industry. The webinars are free to DIA members and will feature topics including oncology, strategies for late phase development, biomarkers and technology as an enabler of clinical development services.

This webinar will address challenges, experiences and best practices for developing and evaluating  Clinical Outcome Assessments (COA’s) and provide an industry perspective on the FDA position on review of COA’s.

Susan Cantrell, Director, North America at DIA said, “It is DIA’s mission to transfer knowledge and timely and pertinent information to health care professionals across the globe.  This series of educational webinars, and this webinar in particular, addresses specific needs for professionals in the areas of medical product development, outcomes research and regulatory affairs. Through our panelists expertise, webinar attendees will be given vital insights and information which will undoubtedly enhance their professional growth.”

Ms. Emuella Flood, Director, Oxford Outcomes, an ICON plc company said, “We are very excited to be a part of this joint effort with DIA to discuss the important and timely topic of COAs for use in drug development.  In this webinar, we will focus particularly on clinician-reported outcomes (ClinROs), which is an area of much discussion among COA researchers. We plan to highlight some of the challenges of applying the PRO guidance to these types of instruments and will offer possible solutions for addressing them.”





ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.

About ICON plc: ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently, operates from 78 locations in 37 countries and has approximately 10,200 employees. Further information is available at www.iconplc.com